What This Bill Does
This bill would amend federal food and drug law to let patients with life-threatening diseases or severely debilitating illnesses use investigational individualized medical treatments. It is aimed at people facing serious conditions who may not have effective standard options and want access to highly personalized therapies that are still under study. The measure would create a pathway for these treatments to be used outside the usual approval process, while still operating within federal oversight of drugs and medical products. In practical terms, it could affect patients, clinicians, researchers, and developers working on custom therapies such as patient-specific biologics or cell-based treatments.
- Amends the Federal Food, Drug, and Cosmetic Act
- Authorizes investigational individualized medical treatments
- Applies to patients with life-threatening disease or severely debilitating illness
- Targets personalized therapies that are still under investigation
- Referred to the House Committee on Energy and Commerce
Who This Bill Affects
For patients with life-threatening or severely debilitating illnesses, this bill could open a new route to try individualized experimental treatments that are otherwise harder to access under standard drug rules. That could be especially important for people with rare diseases or conditions that do not respond to approved therapies. At the same time, it would expose patients to treatments that are still investigational, so the practical effect is greater access with some added uncertainty and risk.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Patients with rare or advanced illnesses They may have exhausted approved options and want access to individualized treatments that could offer a chance of benefit when standard therapies have failed. Supporters see this as a patient-centered way to expand options in urgent situations.
- Physicians treating severe or hard-to-treat conditions Clinicians may want more flexibility to use custom therapies when a patient’s condition is unique and time-sensitive. They may argue that carefully supervised access can be more humane than forcing patients to wait for a conventional approval pathway that does not fit individualized medicine.
- Biotech developers working on personalized therapies Companies and academic teams developing patient-specific treatments may see the bill as a way to create a clearer legal framework for compassionate use and clinical innovation. That could help move promising individualized technologies toward real-world application.
- Patient-safety advocates They may worry that investigational treatments could be used before there is enough evidence that they are safe or effective. In severe illness, desperate patients can be especially vulnerable to unrealistic expectations and harm.
- Public health and regulatory experts They may argue that expanding access outside the normal approval process can weaken the evidence base needed to know whether a treatment truly works. They may also be concerned about inconsistent oversight and uneven standards across providers and products.
- Insurers and payers They may resist pressure to cover expensive individualized experimental treatments that have uncertain outcomes. If coverage is unclear, patients could face high out-of-pocket costs for therapies that are not yet proven.
Key Implications
-
““authorize the use of investigational individualized medical treatments””
This would create a federal pathway for certain custom-made therapies to be used before full approval. For patients, that can mean earlier access; for regulators, it means balancing access with oversight of experimental care.
-
““patients diagnosed with a life-threatening disease or condition or severely debilitating illness””
The bill is aimed at people with the most serious medical needs. That focus limits the policy to high-need cases rather than routine care.
-
““amend the Federal Food, Drug, and Cosmetic Act””
The change would be made through the core federal law governing drugs and medical products. That means the bill would affect how FDA-related rules apply to these treatments.
-
““investigational individualized medical treatments””
The phrase points to therapies tailored to a specific patient rather than mass-produced drugs. In practice, that can include highly personalized approaches that are difficult to regulate under traditional models.
Latest Status
June 8, 2026
Referred to the House Committee on Energy and Commerce.
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.